Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics

Gene Regulation and Systems Biology

Volumn 2008, Issue 2, 2008, Pages 275-295

  Mansoor, Moizza ^a   Melendez, Alirio J ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; AP 12009; APRINOCARSEN; AVI 4126; CGP 69846A; CYCLOSPORIN; DACARBAZINE; EPI 2010; FOMIVIRSEN; GEMCITABINE; GENE EXPRESSION MODULATOR 231; GENE EXPRESSION MODULATOR 92; GTI 2040; ISIS 104838; ISIS 14803; ISIS 2503; ISIS 3521; LIPOSOME ENCAPSULATED C RAF ANTISENSE OLIGODEOXYNUCLEOTIDE; LR 3001; LY 90003; MESALAZINE; MG 98; OBLIMERSEN; OGX 011; OLIGONUCLEOTIDE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PLACEBO; PREDNISONE; RIBOZYME; TRECOVIRSEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ASTHMA; BLEEDING; CANCER SURVIVAL; CHEMICAL MODIFICATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEMENT ACTIVATION; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE INFLAMMATION; FATIGUE; GENOTOXICITY; GRAFT REJECTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE ERYTHEMA; INTERACTIONS WITH RNA; INTRAOCULAR HYPERTENSION; LEUKEMIA; LIPOSOMAL DELIVERY; MONOTHERAPY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PSORIASIS; RESTENOSIS; RETINITIS; REVIEW; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

EID: 67349213986     PISSN: None     EISSN: 11776250     Source Type: Journal    
DOI: 10.4137/grsb.s418     Document Type: Review

References (172)

1. Zhang, Y.C., Taylor, M.M., Samson, W.K. and Phillips, M.I. 2005. Antisense Inhibition. 2nd ed. Antisense Therapeutics, ed. M.I. Phillips., New Jersey: Humana Press.
2. Paterson, B.M., Roberts, B.E. and Kuff, E.L. 1977. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc. Natl. Acad. Sci. U.S.A., 74(10):4370-4.
3. Zamecnik, P.C. and Stephenson, M.L. 1978. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A., 75(1):280-4.
4. Dias, N. and Stein, C.A. 2002. Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther., 1(5):347-55.
5. Vidal, L. et al. 2005. Making sense of antisense. Eur. J. Cancer, 41(18):2812-8.
6. Chen, X. et al. 2005. Chemical modification of gene silencing oligonucleotides for drug discovery and development. Drug Discov. Today, 10(8):587-93.
7. Kurreck, J. 2003. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem., 270(8):1628-44.
8. Sproat, B.S. et al. 1989. Highly efficient chemical synthesis of 2′-Omethyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. Nucleic Acids Res., 17(9):3373-86.
9. Monia, B.P. et al. 1993. Evaluation of 2Pm-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem., 268(19):14514-22.
10. Agrawal, S. et al. 1997. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc. Natl. Acad. Sci. U.S.A., 94(6):2620-5.
11. Fluiter, K. et al. 2003. In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res., 31(3):953-62.
12. Sazani, P. et al. 2002. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol., 20(12):1228-33.
13. Devi, G.R. et al. 2005. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin. Cancer Res., 11(10):3930-8.
14. Kurreck, J. et al. 2002. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res., 30(9):1911-8.
15. Wu, H. et al. 2004. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem., 279(17):17181-9.
16. Baker, B.F. and Monia, B.P. 1999. Novel mechanisms for antisense-mediated regulation of gene expression. Biochim. Biophys. Acta., 1489(1):3-18.
17. Crooke, S.T. 1999. Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta., 1489(1):31-44.
18. Sierakowska, H. et al. 1996. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. U.S.A., 93(23):12840-4.
19. Dias, N. et al. 1999. Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation. J. Mol. Biol., 294(2):403-16.
20. Shoji, Y. et al. 1991. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res., 19(20):5543-50.
21. Zamecnik, P. et al. 1994. Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes. Proc. Natl. Acad. Sci. U.S.A., 91(8):3156-60.
22. Stein, C.A. et al. 1993. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry, 32(18):4855-61.
23. Lysik, M.A. and Wu-Pong, S. 2003. Innovations in oligonucleotide drug delivery. J. Pharm. Sci., 92(8):1559-73.
24. Lebedeva, I. et al. 2000. Cellular delivery of antisense oligonucleotides. Eur. J. Pharm. Biopharm., 50(1):101-19.
25. Farhood, H. et al. 1994. Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann. N. Y. Acad. Sci., 716:23-34; discussion 34-5.
26. Capaccioli, S. et al. 1993. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem. Biophys. Res. Commun., 197(2):818-25.
27. Farhood, H. et al. 1992. Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity. Biochim. Biophys. Acta., 1111(2):239-46.
28. Akhtar, S. et al. 2000. The delivery of antisense therapeutics. Adv. Drug Deliv. Rev., 44(1):3-21.
29. Rojanasakul, Y. et al. 1997. Antisense inhibition of silica-induced tumor necrosis factor in alveolar macrophages. J. Biol. Chem., 272(7):3910-4.
30. Ginobbi, P. et al. 1997. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. Anticancer Res., 17(1A):29-35.
31. Bielinska, A. et al. 1996. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res., 24(11):2176-82.
32. Delong, R. et al. 1997. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J. Pharm. Sci., 86(6):762-4.
33. Morris, M.C. et al. 1997. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res., 25(14):2730-6.
34. Dokka, S. et al. 1997. Cellular delivery of oligonucleotides by synthetic import peptide carrier. Pharm. Res., 14(12):1759-64.
35. de La Torre, B.G. et al. 1999. Synthesis and binding properties of oligonucleotides carrying nuclear localization sequences. Bioconjug. Chem., 10(6):1005-12.
36. Chavany, C. et al. 1994. Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res., 11(9):1370-8.
37. Spiller, D.G. and Tidd, D.M. 1995. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O. Antisense Res. Dev., 5(1):13-21.
38. Zewert, T.E. et al. 1995. Transdermal transport of DNA antisense oligonucleotides by electroporation. Biochem. Biophys. Res. Commun., 212(2):286-92.
39. Huber, P.E. et al. 1999. A comparison of shock wave and sinusoidal-focused ultrasound-induced localized transfection of HeLa cells. Ultrasound Med. Biol., 25(9):1451-7.
40. Stein, C.A., Benimetskaya, L. and Mani, S. 2005. Antisense strategies for oncogene inactivation. Semin. Oncol., 32(6):563-72.
41. Levin, A.A. 1999. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta., 1489(1):69-84.
42. Geary, R.S., Henry, S.P. and Grillone, L.R. 2002. Fomivirsen: clinical pharmacology and potential drug interactions. Clin. Pharmacokinet., 41(4):255-60.
43. Iversen, P. 1991. In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anticancer Drug Des, 6(6):531-8.
44. Grindel, J.M. et al. 1998. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion. Antisense Nucleic Acid Drug Dev., 8(1):43-52.
45. Henry, S.P. et al. 1997. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase. Anticancer Drug Des., 12(5):409-20.
46. Butler, M., Stecker, K. and Bennett, C.F. 1997. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest., 77(4):379-88.
47. Lopes de Menezes, D.E. and Mayer, L.D. 2002. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother. Pharmacol., 49(1):57-68.
48. Sewell, K.L. et al. 2002. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J. Pharmacol. Exp. Ther., 303(3):1334-43.
49. Yu, R.Z. et al. 2004. Tissue disposition of 2′-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J. Pharm. Sci., 93(1):48-59.
50. Arora, V. et al. 2002. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J. Pharm. Sci., 91(4):1009-18.
51. Arora, V., Devi, G.R. and Iversen, P.L. 2004. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr. Pharm. Biotechnol., 5(5):431-9.
52. Lebedeva, I. and Stein, C.A. 2001. Antisense oligonucleotides: promise and reality. Annu. Rev. Pharmacol. Toxicol., 41:403-19.
53. Chan, J.H., Lim, S. and Wong, W.S. 2006. Antisense oligonucleotides: from design to therapeutic application. Clin. Exp. Pharmacol. Physiol., 33(5-6):533-40.
54. Burgess, T.L. et al. 1995. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. U.S.A., 92(9):4051-5.
55. Lang, R. et al. 1999. Guanosine-rich oligodeoxynucleotides induce proliferation of macrophage progenitors in cultures of murine bone marrow cells. Eur. J. Immunol., 29(11):3496-506.
56. Krieg, A.M. 1999. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim. Biophys. Acta., 1489(1):107-16.
57. Krug, A. et al. 2001. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol., 31(10):3026-37.
58. Brazolot Millan, C.L., Weeratna, R., Krieg, A.M., Siegrist, C.A. and Davis, H.L. 1998. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B. surface antigen in young mice. Proc. Natl. Acad. Sci. U.S.A., 95(26):15553-58.
59. Monteith, D.K. et al. 1998. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol. Sci., 46(2):365-75.
60. Crooke, S.T. 2004. Progress in antisense technology. Annu. Rev. Med., 55:61-95.
61. Henry, S.P. et al. 1999. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol. Pathol., 27(1):95-100.
62. Zhou, W. and Agrawal, S. 1998. Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects. Bioorg Med. Chem. Lett., 8(22):3269-74.
63. Reynolds, T. 1992. First antisense drug trials planned in leukemia. J. Natl. Cancer Inst., 84(5):288-90.
64. Wacheck, V. and Zangemeister-Wittke, U. 2006. Antisense molecules for targeted cancer therapy. Crit. Rev. Oncol. Hematol., 59(1):65-73.
65. Whitesell, L., Rosolen, A. and Neckers, L.M. 1991. In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide. Antisense Res. Dev., 1(4):343-50.
66. Gleave, M.E. and Monia, B.P. 2005. Antisense therapy for cancer. Nat. Rev. Cancer, 5(6):468-79.
67. Pirollo, K.F. et al. 2003. Antisense therapeutics: from theory to clinical practice. Pharmacol. Ther., 99(1):55-77.
68. Kitada, S. et al. 1994. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev., 4(2):71-9.
69. Cotter, F.E. et al. 1994. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene., 9(10):3049-55.
70. G 3139. Augmerosen, Bcl-2 antisense oligonucleotide - Genta, GC 3139, Genasense. Drugs R. D3(1):44-9.
71. Waters, J.S. et al. 2000. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol., 18(9):1812-23.
72. Jansen, B. et al. 2000. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet, 356(9243):1728-33.
73. Kirkwood, J.M., Bedikian, A.Y., Millwars, M.J. et al. 2005. Longterm survival results of a randomized multinational phase 3 of dacarbazine (DTIC) with or without bcl-2 antisense (oblimersen sodium)in patients with advanced malignant melanoma. Proc. Am. Soc. Clin. Oncol., 23:711.
74. Ways, D.K. et al. 1995. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J. Clin. Invest., 95(4):1906-15.
75. Yazaki, T. et al. 1996. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol. Pharmacol., 50(2):236-42.
76. McGraw, K. et al. 1997. Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics. Anticancer Drug Des., 12(5):315-26.
77. Geiger, T. et al. 1998. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des., 13(1):35-45.
78. Nemunaitis, J. et al. 1999. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J. Clin. Oncol., 17(11):3586-95.
79. Yuen, A.R. et al. 1999. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res., 5(11):3357-63.
80. Advani, R. et al. 2005. A phase I trial of aprinocarsen (ISIS 3521/ LY.900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Invest. New Drugs, 23(5):467-77.
81. Villalona-Calero, M.A. et al. 2004. A phase I/II study of LY.900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin. Cancer Res., 10(18 Pt 1):6086-93.
82. Marshall, J.L. et al. 2004. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clin. Colorectal Cancer, 4(4):268-74.
83. Ghobrial, I.M. and Adjei, A.A. 2002. Inhibitors of the ras oncogene as therapeutic targets. Hematol. Oncol. Clin. North Am., 16(5):1065-88.
84. Chen, G. et al. 1996. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J. Biol. Chem., 271(45):28259-65.
85. Cunningham, C.C. et al. 2001. A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer, 92(5):1265-71.
86. Alberts, S.R. et al. 2004. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J. Clin. Oncol., 22(24):4944-50.
87. Howe, L.R. et al. 1992. Activation of the MAP kinase pathway by the protein kinase raf. Cell., 71(2):335-42.
88. Wang, H.G., Rapp, U.R. and Reed, J.C. 1996. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell., 87(4):629-38.
89. Storm, S.M. and Rapp, U.R. 1993. Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol. Lett., 67(1-3):201-10.
90. Monia, B.P. et al. 1996. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med., 2(6):668-75.
91. Gokhale, P.C. et al. 1999. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev., 9(2):191-201.
92. O'Dwyer, P.J. et al. 1999. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin. Cancer Res., 5(12):3977-82.
93. Cunningham, C.C. et al. 2000. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res., 6(5):1626-31.
94. Stevenson, J.P. et al. 1999. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol., 17(7):2227-36.
95. Rudin, C.M. et al. 2001. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin. Cancer Res., 7(5):1214-20.
96. Tolcher, A.W. et al. 2002. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin. Cancer Res., 8(8):2530-5.
97. Cripps, M.C. et al. 2002. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clin. Cancer Res., 8(7):2188-92.
98. Oza, A.M. et al. 2003. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecol. Oncol., 89(1):129-33.
99. Coudert, B. et al. 2001. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur. J. Cancer, 37(17):2194-8.
100. Gokhale, P.C. et al. 1997. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer. Gene Ther., 4(12):1289-99.
101. Gokhale, P.C. et al. 2002. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin. Cancer Res., 8(11):3611-21.
102. Pei, J. et al. 2004. Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON.) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs, 15(3):243-53.
103. Kasid, U. and Dritschilo, A. 2003. RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene, 22(37):5876-84.
104. Rudin, C.M. et al. 2004. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin. Cancer Res., 10(21):7244-51.
105. Dritschilo, A. et al. 2006. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin. Cancer Res., 12(4):1251-9.
106. Nichols, W.G. and Boeckh, M. 2000. Recent advances in the therapy and prevention of CMV infections. J. Clin. Virol., 16(1):25-40.
107. Jabs, D.A. and Griffi ths, P.D. 2002. Fomivirsen for the treatment of cytomegalovirus retinitis. Am. J. Ophthalmol., 133(4):552-6.
108. Azad, R.F. et al. 1993. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother., 37(9):1945-54.
109. Anderson, K.P. et al. 1996. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother., 40(9):2004-11.
110. Highleyman, L. 1998. Fomivirsen. Beta, 31:29.
111. Grillone, L.R. and Lanz, R. 2001. Fomivirsen. Drugs Today (Barc), 37(4):245-55.
112. Fomivirsen approved for CMV retinitis: first antisense drug. AIDS Treat News, 1998(302):7.
113. Kim, S.G. et al. 1995. Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus. Bioorg. Med. Chem., 3(1):49-54.
114. Suzuki, J. et al. 2002. Inhibition of human immunodeficiency virus type 1 activity in vitro by a new self-stabilized oligonucleotide with guanosine-thymidine quadruplex motifs. J. Virol., 76(6):3015-22.
115. Matsukura, M. et al. 1989. Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc. Natl. Acad. Sci. U.S.A., 86(11):4244-8.
116. Yamaguchi, K. et al. 1997. The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses, 13(7):545-54.
117. Sereni, D. et al. 1999. Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects. J. Clin. Pharmacol., 39(1):47-54.
118. Zheng, R. 1999. Technology evaluation: GEM-92, Hybridon Inc. Curr. Opin. Mol. Ther., 1(4):521-3.
119. Tan, S.L. et al. 2002. Hepatitis C therapeutics: current status and emerging strategies. Nat. Rev. Drug Discov., 1(11):867-81.
120. Brown-Driver, V. et al. 1999. Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides. Antisense Nucleic Acid Drug Dev., 9(2):145-54.
121. Alt, M. et al. 1995. Specifi c inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology., 22(3):707-17.
122. Zhang, H. et al. 1999. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob. Agents Chemother., 43(2):347-53.
123. Witherell, G.W. 2001. ISIS-14803 (Isis Pharmaceuticals). Curr. Opin. Investig. Drugs, 2(11):1523-9.
124. McHutchison, J.G. et al. 2006. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J. Hepatol., 44(1):88-96.
125. Simmons, D., Makgoba, M.W. and Seed, B. 1988. ICAM, an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM. Nature, 331(6157):624-7.
126. Butcher, E.C. 1991. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell., 67(6):1033-6.
127. Bennett, C.F. et al. 1994. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J. Immunol., 152(7):3530-40.
128. Gewirtz, A.T. and Sitaraman, S.V. 2005. Technology evaluation: alicaforsen (Isis). Curr. Opin. Mol. Ther., 7(3):273-81.
129. Yacyshyn, B.R. et al. 1998. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology, 114(6):1133-42.
130. Schreiber, S. et al. 2001. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology, 120(6):1339-46.
131. Yacyshyn, B.R. et al. 2002. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut., 51(1):30-6.
132. van Deventer, S.J., Tami, J.A. and Wedel, M.K. 2004. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut., 53(11):1646-51.
133. Miner, P. et al. 2004. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol. Ther., 19(3):281-6.
134. Miner, P.B. et al. 2006. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol. Ther., 23(10):1403-13.
135. van Deventer, S.J. et al. 2006. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol. Ther., 23(10):1415-25.
136. Miner, P.B. et al. 2006. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol. Ther., 23(10):1427-34.
137. Kahan, B.D. et al. 2004. Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection. Transplantation, 78(6):858-63.
138. Kast, R.E. 2005. Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities - the role of bupropion. Leuk Res., 29(12):1459-63.
139. Kennewell, P. 2003. Technology evaluation: ISIS-104838, OraSense. Curr. Opin. Mol. Ther., 5(1):76-80.
140. Holmlund, J.T. 2003. Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development. Ann. N. Y. Acad. Sci., 1002:244-51.
141. Spicuzza, L., Di Maria, G. and Polosa, R. 2006. Adenosine in the airways: implications and applications. Eur. J. Pharmacol., 533(1-3):77-88.
142. Bjorck, T., Gustafsson, L.E. and Dahlen, S.E. 1992. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am. Rev. Respir. Dis., 145(5):1087-91.
143. Ali, S., Mustafa, S.J. and Metzger, W.J. 1994. Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late-phase airway obstruction: evidence for an inducible adenosine A1 receptor. J. Pharmacol. Exp. Ther., 268(3):1328-34.
144. Nyce, J.W. 1999. Insight into adenosine receptor function using antisense and gene-knockout approaches. Trends Pharmacol. Sci., 20(2):79-83.
145. Tanaka, M. and Nyce, J.W. 2001. Respirable antisense oligonucleotides: a new drug class for respiratory disease. Respir. Res., 2(1):5-9.
146. Zhang, Z. 2002. Technology evaluation: EPI-2010, EpiGenesis. Curr. Opin. Mol. Ther., 4(3):275-80.
147. Nyce, J.W. and Metzger, W.J. 1997. DNA antisense therapy for asthma in an animal model. Nature, 385(6618):721-5.
148. Ali, S. et al. 2001. Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. Am. J. Respir. Crit. Care Med., 163(4):989-93.
149. Ball, H.A., Van Scott, M.R. and Robinson, C.B. 2004. Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders. Clin. Rev. Allergy Immunol., 27(3):207-17.
150. Egner, U. et al. 2005. The target discovery process. Chembiochem., 6(3):468-79.
151. Borsch-Haubold, A.G., Pasquet, S. and Watson, S.P. 1998. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB. 203580 and PD 98059. SB. 203580 also inhibits thromboxane synthase. J. Biol. Chem., 273(44):28766-72.
152. Taylor, M.F. 2001. Emerging antisense technologies for gene functionalization and drug discovery. DDT, 6(15 (Suppl)):S97-101.
153. Zhi, L., Leung, B.P. and Melendez, A.J. 2006. Sphingosine kinase 1 regulates pro-inflammatory responses triggered by TNFalpha in primary human monocytes. J. Cell. Physiol., 208(1):109-15.
154. Melendez, A.J. and Ibrahim, F.B. 2004. Antisense knockdown of sphingosine kinase 1 in human macrophages inhibits C5a receptor-dependent signal transduction, Ca2+ signals, enzyme release, cytokine production, and chemotaxis. J. Immunol., 173(3):1596-603.
155. Alifano, P. et al. 1994. Ribonuclease E provides substrates for ribonuclease P-dependent processing of a polycistronic mRNA. Genes Dev., 8(24):3021-31.
156. Rossi, J.J. Therapeutic Applications of ribozymes. Nucleic acid therapeutics in cancer, ed. A.M. Gewirtz. 2004, New Jersey: Humana Press 45-8.
157. Haseloff, J. and Gerlach, W.L. 1988. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature, 334(6183):585-91.
158. Sarver, N. et al. 1990. Ribozymes as potential anti-HIV-1 therapeutic agents. Science, 247(4947):1222-5.
159. Pavco, P.A. et al. 2000. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res., 6(5):2094-103.
160. Ngok, F.K. et al. 2004. Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Methods Mol. Biol., 252:581-98.
161. Weng, D.E. et al. 2005. A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol. Cancer Ther., 4(6):948-55.
162. Elbashir, S.M. et al. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411(6836):494-8.
163. Lu, P.Y., Xie, F.Y. and Woodle, M.C. 2003. siRNA-mediated antitumorigenesis for drug target validation and therapeutics. Curr. Opin. Mol. Ther., 5(3):225-34.
164. Reich, S.J. et al. 2003. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis., 9:210-6.
165. Frantz, S. 2006. Safety concerns raised over RNA interference. Nat. Rev. Drug Discov., 5(7):528-9.
166. Bartel, D.P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell., 116(2):281-97.
167. Dugas, D.V. and Bartel, B. 2004. MicroRNA regulation of gene expression in plants. Curr. Opin. Plant Biol., 7(5):512-20.
168. Lee, R.C., Feinbaum, R.L. and Ambros, V. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell., 75(5):843-54.
169. Reinhart, B.J. et al. 2000. The 21 nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature, 403(6772):901-06.
170. Carrington, J.C. and Ambros, V. 2003. Role of microRNAs in plant and animal development. Science, 301(5631):336-8.
171. Phillips, M.I. Antisense therapeutics. A promise waiting to be fulfilled. 2nd ed. Antisense Therapeutics, ed. M.I. Phillips. 2005, New Jersey: Humana Press.
172. Frantz, S. 2004. Lessons learnt from Genasense's failure. Nat. Rev. Drug Discov., 3(7):542-3.